AI-generated analysis. Always verify with the original filing.
Sight Sciences, Inc. reported Q4 2025 total revenue of $20.4 million, up 7% year-over-year, and full year 2025 revenue of $77.4 million, down 3% from 2024, with improved gross margins and reduced operating expenses. The company initiated 2026 revenue guidance of $82-88 million and posted an investor presentation.
Event Type
Disclosure
Mandatory
Variant
8-K
, Item 7.01, Exhibit 99.1 and Exhibit 99.2 of this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,
Regulation FD Disclosure On March 4, 2026, the Company posted an investor presentation to its website at https://investors.sightsciences.com/. The Company expec
Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Earnings Press Release dated March 4, 2026 99.2 Sight Sciences Presentation dated Ma
| Metric | Value | Basis |
|---|---|---|
| Revenue | $77.40 | |
| Interventional Glaucoma Revenue | $75.70 | |
| Interventional Dry Eye Revenue | $1.60 | |
| Gross Profit | $66.70 | |
| Gross Margin | 86% | |
| Total Operating Expenses | $103.80 | GAAP |
| Adjusted Operating Expenses | $87.80 | Non-GAAP |
| Net Loss | $-38.40 | |
| Diluted EPS | $-0.74 |
Revenue
88
Interventional Glaucoma Revenue
81
Interventional Dry Eye Revenue
7
Adjusted Operating Expenses
96
Non-GAAP